Location:
Berg Family Foundation Seminar Room, Level 6, Wallace Wurth Building, Kensington Campus
A catered lunch will be provided at 12:30pm. Please RSVP to recpt@kirby.unsw.edu.au by COB Friday 31 May.
Kirby Institute Seminar Series presents
 |
Associate Lecturer, Viral Hepatitis Clinical Research Program, Kirby Institute, UNSW Sydney Sahar Bajis is an Associate Lecturer in the Viral Hepatitis Clinical Research Program at the Kirby Institute, UNSW Sydney. She holds a master's degree in International Public Health and has recently completed her PhD in clinical epidemiology at the Kirby Institute. Her PhD focused on investigating strategies to enhance the HCV care cascade in marginalised populations. Sahar is a registered pharmacist with extensive experience in clinical/hospital and community pharmacy and as a humanitarian field worker (with Médecins Sans Frontières). She has a keen interest in global health and the right of all to access affordable and quality healthcare. |
Abstract
The introduction of direct-acting antiviral (DAA) therapy has transformed the clinical management of hepatitis C virus (HCV) infection and given impetus to the WHO goal of eliminating HCV infection as a public health threat by 2030. Although DAA therapy has provided the tools to achieve this, HCV elimination is contingent on substantially increasing the number of people tested, diagnosed, linked to care and treated. Improving the HCV care cascade among marginalised high-risk populations of people who inject drugs and people who are homeless is paramount in these efforts. This seminar presents findings from the evaluation of the feasibility and outcomes of strategies to enhance the HCV care cascade among marginalised populations pre- and post-access to DAA therapy.